The need to define treatment goals for systemic lupus erythematosus

Research output: Contribution to journalReview ArticleResearchpeer-review

25 Citations (Scopus)

Abstract

In the current therapeutic climate, mortality rates from systemic lupus erythematosus (SLE) remain unacceptably high. Although new therapies are on the horizon, pending their emergence and availability, optimization of the currently available therapies is potentially achievable. A treat-to-target approach is now considered routine for many diseases, including rheumatoid arthritis, for which it has substantially improved patient outcomes. The heterogeneity of SLE, as well as lack of universal agreement over methods to measure disease activity and treatment responses, has impeded the development of such an approach for this disease. In this article, the potential benefits of a treatment-target definition are explored, obstacles to the development of a treatment target in SLE are identified, and possible strategies to achieve this goal are discussed.
Original languageEnglish
Pages (from-to)567 - 571
Number of pages5
JournalNature Reviews Rheumatology
Volume10
Issue number9
DOIs
Publication statusPublished - 2014

Cite this

@article{1e0c0963fba144b3af7c0cf7fcc44d44,
title = "The need to define treatment goals for systemic lupus erythematosus",
abstract = "In the current therapeutic climate, mortality rates from systemic lupus erythematosus (SLE) remain unacceptably high. Although new therapies are on the horizon, pending their emergence and availability, optimization of the currently available therapies is potentially achievable. A treat-to-target approach is now considered routine for many diseases, including rheumatoid arthritis, for which it has substantially improved patient outcomes. The heterogeneity of SLE, as well as lack of universal agreement over methods to measure disease activity and treatment responses, has impeded the development of such an approach for this disease. In this article, the potential benefits of a treatment-target definition are explored, obstacles to the development of a treatment target in SLE are identified, and possible strategies to achieve this goal are discussed.",
author = "Kate Franklyn and Alberta Hoi and Mandana Nikpour and Morand, {Eric F.}",
year = "2014",
doi = "10.1038/nrrheum.2014.118",
language = "English",
volume = "10",
pages = "567 -- 571",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "9",

}

The need to define treatment goals for systemic lupus erythematosus. / Franklyn, Kate; Hoi, Alberta; Nikpour, Mandana; Morand, Eric F.

In: Nature Reviews Rheumatology, Vol. 10, No. 9, 2014, p. 567 - 571.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The need to define treatment goals for systemic lupus erythematosus

AU - Franklyn, Kate

AU - Hoi, Alberta

AU - Nikpour, Mandana

AU - Morand, Eric F.

PY - 2014

Y1 - 2014

N2 - In the current therapeutic climate, mortality rates from systemic lupus erythematosus (SLE) remain unacceptably high. Although new therapies are on the horizon, pending their emergence and availability, optimization of the currently available therapies is potentially achievable. A treat-to-target approach is now considered routine for many diseases, including rheumatoid arthritis, for which it has substantially improved patient outcomes. The heterogeneity of SLE, as well as lack of universal agreement over methods to measure disease activity and treatment responses, has impeded the development of such an approach for this disease. In this article, the potential benefits of a treatment-target definition are explored, obstacles to the development of a treatment target in SLE are identified, and possible strategies to achieve this goal are discussed.

AB - In the current therapeutic climate, mortality rates from systemic lupus erythematosus (SLE) remain unacceptably high. Although new therapies are on the horizon, pending their emergence and availability, optimization of the currently available therapies is potentially achievable. A treat-to-target approach is now considered routine for many diseases, including rheumatoid arthritis, for which it has substantially improved patient outcomes. The heterogeneity of SLE, as well as lack of universal agreement over methods to measure disease activity and treatment responses, has impeded the development of such an approach for this disease. In this article, the potential benefits of a treatment-target definition are explored, obstacles to the development of a treatment target in SLE are identified, and possible strategies to achieve this goal are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84908099269&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2014.118

DO - 10.1038/nrrheum.2014.118

M3 - Review Article

VL - 10

SP - 567

EP - 571

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 9

ER -